PARD (Poniard Pharmaceuticals) Total Operating Expense: $15.53 Mil (TTM As of Sep. 2011)


What is Poniard Pharmaceuticals Total Operating Expense?

Poniard Pharmaceuticals PARD Total Operating Expense is $15.53 Mil as of Sep. 2011.

Poniard Pharmaceuticals's Total Operating Expense for the three months ended in Sep. 2011 was $3.75 Mil. Poniard Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2011 was $15.53 Mil.

Poniard Pharmaceuticals Total Operating Expense Related Terms

Poniard Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Total Operating Expense Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.23 35.35 49.16 40.44 26.33

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.95 4.72 3.23 3.84 3.75

Poniard Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $15.53 Mil mean?
Poniard Pharmaceuticals (PARD) has a Total Operating Expense of $15.53 Mil as of Sep. 2011. Total operating expense is the primary recurring expense associated with central operations. View historical data on Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' Total Operating Expense too high?
Poniard Pharmaceuticals' current Total Operating Expense is $15.53 Mil.
How does Poniard Pharmaceuticals' Total Operating Expense compare to OBMP and NSPX?
Poniard Pharmaceuticals' Total Operating Expense of $15.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current Total Operating Expense is $15.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current Total Operating Expense of $15.53 Mil. The current Total Operating Expense is $15.53 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current Total Operating Expense is $15.53 Mil as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.